Drug Profile


Alternative Names: NKY 722

Latest Information Update: 21 Sep 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Kyoto Pharmaceutical Industries; Senju Pharmaceutical
  • Developer ISTA Pharmaceuticals
  • Class Antihypertensives; Piperazines; Pyridines
  • Mechanism of Action Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Glaucoma

Most Recent Events

  • 21 Sep 2010 Discontinued - Phase-I for Glaucoma in USA (Ophthalmic)
  • 14 May 2009 Phase I development is ongoing in USA
  • 21 Jun 2006 Iganidipine has been licensed to ISTA Pharmaceuticals in North America
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top